Merkel cell carcinomas (MCCs) exhibit diverse molecular profiles, often categorized by their association with Merkel cell polyoma virus (MCPyV). MCPyV-associated MCCs typically display a low tumor mutational burden (TMB), lacking both somatic mutations and ultraviolet signature. By contrast, MCPyV-negative MCCs commonly arise in sun-exposed skin and frequently exhibit a high TMB, along with TERT promoter mutation (TPM) and somatic mutations, particularly in TP53 and RB1. Gene fusions are exceedingly rare in MCCs, and their specific frequency and fusion transcripts remain largely unexplored. Here, we present a unique case of MCPyV-associated MCC characterized by NSD3::FGFR1 fusion, representing a novel fusion transcript not previously reported in MCCs. A 72-year-old White man presented with a cyst-like nodule on the left elbow, which had progressively increased in size over a span of 6 months. Excisional biopsy specimen revealed a neuroendocrine carcinoma diffusely expressing CK20 (perinuclear dot-like), synaptophysin, CD56, NSE, and MCPyV, consistent with MCC. Next-generation sequencing identified a NSD3::FGFR1 fusion without any additional somatic mutations, including TP53 and RB1 mutations, or TPM. Although NSD3::FGFR1 fusion has been sporadically reported in other solid tumors, such as pulmonary squamous cell carcinoma, its identification in an MCC is unprecedented to our knowledge. This novel finding not only underscores the uniqueness of our case but also contributes to the evolving understanding of the molecular landscape of MCCs, particularly MCPyV-associated MCCs.

Download full-text PDF

Source
http://dx.doi.org/10.1097/DAD.0000000000002953DOI Listing

Publication Analysis

Top Keywords

merkel cell
12
somatic mutations
12
nsd3fgfr1 fusion
12
cell carcinoma
8
mcpyv-associated mccs
8
tp53 rb1
8
mccs
7
fusion
6
nsd3fgfr1
4
nsd3fgfr1 novel
4

Similar Publications

Background And Objectives: This study aimed to describe the clinical and prognostic characteristics of antibody-positive paraneoplastic neurological syndrome (PNS) associated with immune checkpoint inhibitors (ICIs).

Methods: We conducted a systematic review of relevant publications in PubMed and Embase from inception to December 2023. Patients with positive anti-neuronal antibodies who had a definite, probable, or possible diagnosis of PNS based on the 2021 PNS-Care Score criteria were included.

View Article and Find Full Text PDF

Background: Prognosis and quality of life of advanced cutaneous T cell lymphoma (CTCL) patients, in particular those with Sézary syndrome (SS) and advanced-stage mycosis fungoides (MF), are poor. Monoclonal antibodies or antibody-drug conjugates (ADCs) have been implemented into CTCL therapy algorithms, but the spectrum of antibody-targetable cell-surface antigens on T cell non-Hodgkin lymphomas (T-NHL) is limited.

Objectives: To evaluate expression of the MHC-II chaperone CD74 across common subtypes of CTCL by various methods, and to explore the efficacy of CD74-targeting of CTCL cells by anti-CD74 antibody-drug conjugate (ADC) in vitro and in vivo.

View Article and Find Full Text PDF

Merkel cell carcinomas (MCCs) exhibit diverse molecular profiles, often categorized by their association with Merkel cell polyoma virus (MCPyV). MCPyV-associated MCCs typically display a low tumor mutational burden (TMB), lacking both somatic mutations and ultraviolet signature. By contrast, MCPyV-negative MCCs commonly arise in sun-exposed skin and frequently exhibit a high TMB, along with TERT promoter mutation (TPM) and somatic mutations, particularly in TP53 and RB1.

View Article and Find Full Text PDF

The significance of PAX5 in Merkel cell carcinoma.

J Pathol

March 2025

Department of Pathology, GROW-Research Institute for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht, The Netherlands.

Merkel cell carcinoma (MCC) is a highly malignant skin cancer that expresses epithelial-, neuroendocrine-, and lymphoid-associated genes. Here, we focused on B-cell differentiation, which is characterised by the coexpression of PAX5 and TdT. PAX5 is the master regulator of B-cell commitment and is expressed in 65% of MCC cases.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!